119 related articles for article (PubMed ID: 14733590)
1. A comparative study of different presentation strategies for an HIV peptide immunogen.
Cruz LJ; Iglesias E; Aguilar JC; González LJ; Reyes O; Albericio F; Andreu D
Bioconjug Chem; 2004; 15(1):112-20. PubMed ID: 14733590
[TBL] [Abstract][Full Text] [Related]
2. Different immune response of mice immunized with conjugates containing multiple copies of either consensus or mixotope versions of the V3 loop peptide from human immunodeficiency virus type 1.
Cruz LJ; Iglesias E; Aguilar JC; Cabrales A; Reyes O; Andreu D
Bioconjug Chem; 2004; 15(5):1110-7. PubMed ID: 15366967
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity comparison of a multi-antigenic peptide bearing V3 sequences of the human immunodeficiency virus type 1 with TAB9 protein in mice.
Cruz LJ; Quintana D; Iglesias E; Garcia Y; Huerta V; Garay HE; Duarte C; Reyes O
J Pept Sci; 2000 May; 6(5):217-24. PubMed ID: 10823490
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity and cross-reactivity of HIV-1 V3-peptide and multiple antigen peptides conjugated to distinct carrier proteins.
Cruz LJ; Cabrales A; Iglesias E; Aguilar JC; González LJ; Reyes O
Int Immunopharmacol; 2009 Nov; 9(12):1452-9. PubMed ID: 19747570
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
6. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg.
Iglesias E; Aguilar JC; Cruz LJ; Reyes O
Mol Immunol; 2005 Jan; 42(1):99-104. PubMed ID: 15488948
[TBL] [Abstract][Full Text] [Related]
7. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
8. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines.
Maksyutov AZ; Bachinskii AG; Bazhan SI; Ryzhikov EA; Maksyutov ZA
J Clin Virol; 2004 Dec; 31 Suppl 1():S26-38. PubMed ID: 15567091
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
Hewer R; Meyer D
Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
[TBL] [Abstract][Full Text] [Related]
10. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines.
Megede JZ; Otten GR; Doe B; Liu H; Srivastava R; Greer C; Legg H; Tang T; Polo JM; Donnelly JJ; Ulmer JB; Barnett SW
Vaccine; 2006 Apr; 24(15):2755-63. PubMed ID: 16460840
[TBL] [Abstract][Full Text] [Related]
12. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
[TBL] [Abstract][Full Text] [Related]
13. Peptide based vaccine design: synthesis and immunological characterization of branched polypeptide conjugates comprising the 276-284 immunodominant epitope of HSV-1 glycoprotein D.
Mezo G; Dalmadi B; Mucsi I; Bosze S; Rajnavölgyl E; Hudecz F
J Pept Sci; 2002 Mar; 8(3):107-17. PubMed ID: 11931583
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity evaluation of a lipidic amino acid-based synthetic peptide vaccine for Chlamydia trachomatis.
Zhong G; Toth I; Reid R; Brunham RC
J Immunol; 1993 Oct; 151(7):3728-36. PubMed ID: 7690812
[TBL] [Abstract][Full Text] [Related]
15. [Composition of HIV-1 B-epitopes and heterologous T-cell epitopes. I. Maintenance of antigenic properties of HIV-1 B-epitopes].
Isaguliants MG; Koshida R; Ruden U; Varen B
Biokhimiia; 1996 Jul; 61(7):1221-9. PubMed ID: 9035735
[TBL] [Abstract][Full Text] [Related]
16. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
[TBL] [Abstract][Full Text] [Related]
17. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
[TBL] [Abstract][Full Text] [Related]
18. Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine.
De Groot AS; Bishop EA; Khan B; Lally M; Marcon L; Franco J; Mayer KH; Carpenter CC; Martin W
Methods; 2004 Dec; 34(4):476-87. PubMed ID: 15542374
[TBL] [Abstract][Full Text] [Related]
19. Overcoming original (antigenic) sin.
Anderson DE; Carlos MP; Nguyen L; Torres JV
Clin Immunol; 2001 Nov; 101(2):152-7. PubMed ID: 11683574
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
